Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
TAVR among 90-year-old patients: An updated look at mortality & more | FDA approves new heart failure drug
Wednesday, May 31, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

TAVR among 90-year-old patients: An updated look at mortality, hospital costs and more

In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 

READ MORE >
Treating elderly atrial fibrillation (AFib) patients—even those who are traditionally ineligible for direct oral anticoagulants (DOACs)—with a very low dose of edoxaban is associated with improved outcomes, according to new research published in JAMA Network Open.
Share on Twitter Share on Facebook Share on Linkedin

TAVR among 90-year-old patients: An updated look at mortality, hospital costs and more

Share on Twitter Share on Facebook Share on Linkedin
Treating elderly atrial fibrillation (AFib) patients—even those who are traditionally ineligible for direct oral anticoagulants (DOACs)—with a very low dose of edoxaban is associated with improved outcomes, according to new research published in JAMA Network Open.
In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 
READ MORE >

FDA approves sotagliflozin, the new heart failure drug from Lexicon Pharmaceuticals

The drug, which should be available by the end of June, will be marketed under the name Inpefa.

READ MORE >
approved approval
Share on Twitter Share on Facebook Share on Linkedin

FDA approves sotagliflozin, the new heart failure drug from Lexicon Pharmaceuticals

Share on Twitter Share on Facebook Share on Linkedin
approved approval
The drug, which should be available by the end of June, will be marketed under the name Inpefa.
READ MORE >

Featured Articles

Salary update: Cardiologist compensation climbs to $507K per year, though many feel it is too low

Cardiology came in at No. 3 among all healthcare specialties, trailing only plastic surgery ($619,000) and orthopedics ($573,000).

READ MORE >
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Share on Twitter Share on Facebook Share on Linkedin

Salary update: Cardiologist compensation climbs to $507K per year, though many feel it is too low

Share on Twitter Share on Facebook Share on Linkedin
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Cardiology came in at No. 3 among all healthcare specialties, trailing only plastic surgery ($619,000) and orthopedics ($573,000).
READ MORE >

Key takeaways from Heart Rhythm 2023

Kenneth Ellenbogen, MD, detailed some of the biggest trends he saw at the three-day event in New Orleans. 

READ MORE >
Kenneth Ellenbogen, MD, explains the key EP takeaways from the 2023 Heart Rhythm Society meeting.
Share on Twitter Share on Facebook Share on Linkedin

Key takeaways from Heart Rhythm 2023

Share on Twitter Share on Facebook Share on Linkedin
Kenneth Ellenbogen, MD, explains the key EP takeaways from the 2023 Heart Rhythm Society meeting.
Kenneth Ellenbogen, MD, detailed some of the biggest trends he saw at the three-day event in New Orleans. 
READ MORE >

AI organizes heart failure patients into 5 distinct groups, helping cardiologists manage care

Researchers used multiple AI models to evaluate EHR data from more than 322,000 heart failure patients. By identifying these subtypes, the group thinks clinicians could perform better risk assessments and make more informed treatment decisions. 

READ MORE >
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Share on Twitter Share on Facebook Share on Linkedin

AI organizes heart failure patients into 5 distinct groups, helping cardiologists manage care

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Researchers used multiple AI models to evaluate EHR data from more than 322,000 heart failure patients. By identifying these subtypes, the group thinks clinicians could perform better risk assessments and make more informed treatment decisions. 
READ MORE >

In Case You Missed It

Innovation in the cath lab: Cardiologists develop, perform new interventional heart procedure

Interventional cardiologists in Detroit developed the new technique with a specific patient in mind. One specialist described it as an "exciting breakthrough."

READ MORE >
Cardiologist heart
Share on Twitter Share on Facebook Share on Linkedin

Innovation in the cath lab: Cardiologists develop, perform new interventional heart procedure

Share on Twitter Share on Facebook Share on Linkedin
Cardiologist heart
Interventional cardiologists in Detroit developed the new technique with a specific patient in mind. One specialist described it as an "exciting breakthrough."
READ MORE >

WHO warns against use of artificial sweeteners, highlighting CVD and diabetes risks

The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.

READ MORE >
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
Share on Twitter Share on Facebook Share on Linkedin

WHO warns against use of artificial sweeteners, highlighting CVD and diabetes risks

Share on Twitter Share on Facebook Share on Linkedin
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
READ MORE >

In Other News

Integra poised to take $60 million hit following voluntary recall of devices manufactured at Boston facility

Production of Integra’s SurgiMend, PriMatrix, Revize and TissueMend products has been temporarily halted due to the recalls, although the company said it has not received any customer complaints. 

READ MORE >
Recall | Product recall
Share on Twitter Share on Facebook Share on Linkedin

Integra poised to take $60 million hit following voluntary recall of devices manufactured at Boston facility

Share on Twitter Share on Facebook Share on Linkedin
Recall | Product recall
Production of Integra’s SurgiMend, PriMatrix, Revize and TissueMend products has been temporarily halted due to the recalls, although the company said it has not received any customer complaints. 
READ MORE >

FDA approval of several impactful drugs could be delayed if US defaults on debt

The FDA’s process of reviewing and approving drugs and devices could be put on hold, if lawmakers fail to reach a deal related to the debt ceiling.

READ MORE >
Medical societies are asking Congress to be involved in Medicare reform efforts.
Share on Twitter Share on Facebook Share on Linkedin

FDA approval of several impactful drugs could be delayed if US defaults on debt

Share on Twitter Share on Facebook Share on Linkedin
Medical societies are asking Congress to be involved in Medicare reform efforts.
The FDA’s process of reviewing and approving drugs and devices could be put on hold, if lawmakers fail to reach a deal related to the debt ceiling.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup